Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: N06AX21

Duloxetine Boehringer Ingelheim(duloxetine)

Diabetic Neuropathies

Marketing Authorisation Holder: Boehringer Ingelheim International GmbH

EMA Authorisation: 08/10/2008

INN: duloxetine

Indication

Treatment of diabetic peripheral neuropathic pain in adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Duloxetine Boehringer Ingelheim — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.